See how CAR-T response depends on tumor features
Part of Blood & lymphatic clinical trials.
This study looks at how well CAR-T cell therapy works in people with blood cancers like lymphoma, ALL, or multiple myeloma, and whether tumor features affect the response. It may help doctors predict who benefits most and how to personalize future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer such as lymphoma, ALL, or multiple myeloma
- You are enrolled in a CAR-T treatment program
- You are age 15 or older (or have consent from a parent/guardian if under 18)
- You weigh at least 58 kg
- You are not currently receiving another treatment at the same time as CAR-T
- You are not under court-appointed guardianship/curatorship, and you have health coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This study collects blood and tissue samples from adults receiving CAR-T cell therapy (an advanced cancer treatment) to understand why it works well for some patients but not others. The goal is to find biological markers that predict treatment success.
This study aims to create models that predict how well patients with non-Hodgkin lymphoma will respond to CAR-T cell therapy and how likely they are to have side effects. It may help doctors tailor treatment for people whose lymphoma has not improved or has come back.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This Phase 1 trial tests CAR-T cell therapy (immune cells modified to target cancer) in people whose blood cancers came back or didn’t respond to standard treatments. If you qualify, the study aims to see whether this treatment can fight the cancer and how safe it is.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.